Huahao Zhongtian Pharmaceutical has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares
Huahao Zhongtian Pharmaceutical (02563.HK) announced that the company has received a filing notice from the China Securities Regulatory Commission regarding its application issued on February 5, 2026. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares. The filing notice will be valid for 12 months from the date of issuance and will apply to the Stock Exchange for conversion and listing. However, the details of the conversion and listing implementation plan have not yet been finalized
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments